Saturday, 31 October 2026European Markets

CHARGEURS And S.E.B. Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - chargeurs (cri.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
chargeurs (cri.pa) €10.50 9.42% 5.45%
s.e.b. (sk.pa) €100.80 2.76% 11.11%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. chargeurs (cri.pa)

9.42% forward dividend yield and 5.45% return on equity

chargeurs sa operates as a manufacturing and services company in france, europe, the americas, asia, and internationally. the company operates through luxury and technologies segments. it provides surface solutions, such as plastic and paper films, technical adhesives, and application machinery for manufacturers of surfaces or products comprising plastics, glass, stainless steel, aluminum, pre-coated metals, and polyvinyl chloride (pvc) profiles; interlinings for the luxury and fashion industries; accessories and leather goods; and supplies wool fibers. the company is also involved in the production and sale of coats, jackets, shirts, sports clothing, and other products; and production and distribution of personal protective equipment. in addition, it offers various solutions, including strategic consulting, master planning, design, development, publishing, curation, exhibitions, marketing, merchandising, digital content, communication, etc.; and the museum studio platform that includes a portfolio of services comprising project coordination and museum installations, as well as design and the creation of immersive and technological experiences, and production of audiovisual content and the publication of art books. the company was formerly known as chargetex 1 and changed its name to chargeurs sa in 1997. chargeurs sa was founded in 1872 and is headquartered in paris, france.

earnings per share

as for profitability, chargeurs has a trailing twelve months eps of €0.92.

pe ratio

chargeurs has a trailing twelve months price to earnings ratio of 11.41. meaning, the purchaser of the share is investing €11.41 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.45%.

yearly top and bottom value

chargeurs's stock is valued at €10.50 at 02:30 est, way below its 52-week high of €16.09 and way above its 52-week low of €7.67.

more news about chargeurs.

2. s.e.b. (sk.pa)

2.76% forward dividend yield and 11.11% return on equity

seb sa designs, manufactures, and markets small domestic equipment worldwide. it offers kitchen electrics including electrical cooking products, such as deep fryers, rice cookers, electrical pressure cookers, informal meal appliances, waffle makers, grills, toasters, and multicookers; beverage preparation products, which includes filter and pod coffee makers, espresso machines, electrical kettles, and home beer-taps; and food preparation products comprising blenders, soy milk makers, cooking food processors, kitchen machines, mixers, and beaters. the company also provides home and personal care, which includes linen care, such as irons and steam generators, and garment steamers; canister vacuum cleaners with or without dust bag, steam and upright vacuum cleaners and sweepers, and versatile vacuums, and robots; home comfort products, such as fans, heaters, and air purifiers; and personal care products including hair care appliances, depilators, electrical beard trimmers and hair clippers, and bathroom scales. in addition, it offers cookware comprising frying pans, saucepans, woks, pressure cookers, bakeware, kitchen utensils, food storage containers, vacuum flasks, and mugs. the company provides its products under various consumer brands including aron, asia vina, calor, clock, emsa, imusa, kaiser, krupus, maharaj whiteline, mirro, moulinex, obh nordica, panex, rochedo, rowenta, samurai, seb, supor, tefal t-fal, umco, and wearever brands. further, it offers under premium brands, which includes all-clad, krampouz, lagostina, silit, and wmf brands; and professional brands, such as hepp, schaerer coffee procare, wilbur curtis, and zummo brands. the company was founded in 1857 and is headquartered in écully, france.

earnings per share

as for profitability, s.e.b. has a trailing twelve months eps of €5.8.

pe ratio

s.e.b. has a trailing twelve months price to earnings ratio of 17.38. meaning, the purchaser of the share is investing €17.38 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.11%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, s.e.b.'s stock is considered to be oversold (<=20).

more news about s.e.b..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com